BioAegis Therapeutics Expands Phase 1b/2a Community-Acquired Pneumonia Study to the Republic of Georgia —Successfully Completes Second of Four Dosing Cohorts
07. Februar 2019 09:17 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that patient enrollment is underway in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in...